Pushing the frontiers of T-cell vaccines: Accurate measurement of human T-cell responses

Expert Review of Vaccines

Volumn 11, Issue 12, 2012, Pages 1459-1470

  Saade, Fadi ^a   Gorski, Stacey Ann ^a,b   Petrovsky, Nikolai ^a,c  

^a VAXINE PTY LTD   (Australia)

^b UNIVERSITY OF VIRGINIA   (United States)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

clinical trials; CTL; CYTOF; ELISPOT; flow cytometry; T cell assay; vaccine

Indexed keywords

PHOSPHOPROTEIN; T CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

CELL PROLIFERATION; CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOPHENOTYPING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; IMMUNOASSAY; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; VACCINES;

EID: 84871558491     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.125     Document Type: Review

References (114)

1. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 406(6797), 793-798 (2000).
2. Mallone R, Mannering SI, Brooks-Worrell BM et al.; T-Cell Workshop Committee, Immunology of Diabetes Society. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 163(1), 33-49 (2011).
3. Costantini A, Mancini S, Giuliodoro S et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J. Immunol. Methods 278(1-2), 145-155 (2003).
4. Goodell V, dela Rosa C, Slota M, MacLeod B, Disis ML. Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol. 8, 21 (2007).
5. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243(1-2), 147-154 (2000).
6. de Souza MS, Ratto-Kim S, Chuenarom W et al.; Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Collaborators. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 188(10), 5166-5176 (2012).
7. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171(1), 131-137 (1994).
8. Last'ovicka J, Budinský V, Spísek R, Bartunková J. Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers. Cell. Immunol. 256(1-2), 79-85 (2009).
9. Leif RC, Stein JH, Zucker RM. A short history of the initial application of anti-5-BrdU to the detection and measurement of S phase. Cytometry. A 58(1), 45-52 (2004).
10. Shedlock DJ, Talbott KT, Morrow MP et al. Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo. Cytometry. A 77(3), 275-284 (2010).
11. Stubbe M, Vanderheyde N, Goldman M, Marchant A. Antigen-specific central memory CD4+ T lymphocytes produce multiple cytokines and proliferate in vivo in humans. J. Immunol. 177(11), 8185-8190 (2006).
12. Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 12(9), 812-818 (1994).
13. Heeg K, Reimann J, Kabelitz D, Hardt C, Wagner H. A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J. Immunol. Methods 77(2), 237-246 (1985).
14. Kaplan DR, Griffith R, Braciale VL, Braciale TJ. Influenza virus-specific human cytotoxic T cell clones: heterogeneity in antigenic specificity and restriction by class II MHC products. Cell. Immunol. 88(1), 193-206 (1984).
15. Han Q, Bagheri N, Bradshaw EM, Hafler DA, Lauffenburger DA, Love JC. Polyfunctional responses by human T cells result from sequential release of cytokines. Proc. Natl Acad. Sci. USA 109(5), 1607-1612 (2012).
16. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
17. Yamane H, Paul WE. Memory CD4+ T cells: fate determination, positive feedback and plasticity. Cell. Mol. Life Sci. 69(10), 1577-1583 (2012).
18. Petrovsky N, Harrison LC. Cytokine-based human whole blood assay for the detection of antigen-reactive T cells. J. Immunol. Methods 186(1), 37-46 (1995).
19. Carson RT, Desai DD, Vignali KM, Vignali DA. Immunoregulation of Th cells by naturally processed peptide antagonists. J. Immunol. 162(1), 1-4 (1999).
20. Flagella M, Bui S, Zheng Z et al. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal. Biochem. 352(1), 50-60 (2006).
21. Zheng Z, Luo Y, McMaster GK. Sensitive and quantitative measurement of gene expression directly from a small amount of whole blood. Clin. Chem. 52(7), 1294-1302 (2006).
22. Bomert M, Köllisch G, Roponen M et al. Analytical performance of a multiplexed, bead-based cytokine detection system in small volume samples. Clin. Chem. Lab. Med. 49(10), 1691-1693 (2011).
23. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J. Immunol. Methods 340(1), 55-64 (2009).
24. Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38(4), 317-323 (2006).
25. Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP Jr. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B. Clin. Cytom. 61(1), 35-39 (2004).
26. Richens JL, Urbanowicz RA, Metcalf R, Corne J, O'Shea P, Fairclough L. Quantitative validation and comparison of multiplex cytokine kits. J. Biomol. Screen. 15(5), 562-568 (2010).
27. Defawe OD, Fong Y, Vasilyeva E et al. Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells. J. Immunol. Methods 382(1-2), 117-128 (2012).
28. Lalor MK, Floyd S, Gorak-Stolinska P et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J. Infect. Dis. 204(7), 1075-1085 (2011).
29. Shebl FM, Pinto LA, García-Piñeres A et al. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol. Biomarkers Prev. 19(4), 978-981 (2010).
30. Dabitao D, Margolick JB, Lopez J, Bream JH. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J. Immunol. Methods 372(1-2), 71-77 (2011).
31. Lehmann PV, Zhang W. Unique strengths of ELISPOT for T cell diagnostics. Methods Mol. Biol. 792, 3-23 (2012).
32. De Rosa SC, Lu FX, Yu J et al. Vaccination in humans generates broad T cell cytokine responses. J. Immunol. 173(9), 5372-5380 (2004).
33. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99(7), 1739-1750 (1997).
34. Lovelace P, Maecker HT. Multiparameter intracellular cytokine staining. Methods Mol. Biol. 699, 165-178 (2011).
35. Maecker HT, Rinfret A, D'Souza P et al. Standardization of cytokine flow cytometry assays. BMC Immunol. 6, 13 (2005).
36. Karlsson AC, Martin JN, Younger SR et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J. Immunol. Methods 283(1-2), 141-153 (2003).
37. Maecker HT, Hassler J, Payne JK et al. Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 9, 9 (2008).
38. Assenmacher M, Löhning M, Radbruch A. Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay. Curr. Protoc. Immunol. Chapter 6, Unit 6.27 (2002).
39. Campbell JD, Foerster A, Lasmanowicz V et al. Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion. Clin. Exp. Immunol. 163(1), 1-10 (2011).
40. Sojka DK, Fowell DJ. Regulatory T cells inhibit acute IFN-γ synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proc. Natl Acad. Sci. USA 108(45), 18336-18341 (2011).
41. Versteegen JM, Logtenberg T, Ballieux RE. Enumeration of IFN-γ-producing human lymphocytes by spot-ELISA. A method to detect lymphokine-producing lymphocytes at the single-cell level. J. Immunol. Methods 111(1), 25-29 (1988).
42. Zhang W, Caspell R, Karulin AY et al. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring-even in hands of ELISPOT-inexperienced investigators. J. Immunotoxicol. 6(4), 227-234 (2009).
43. Hill PC, Brookes RH, Fox A et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 4(6), e192 (2007).
44. Kester KE, Cummings JF, Ockenhouse CF et al.; RTS,S Malaria Vaccine Evaluation Group. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26(18), 2191-2202 (2008).
45. Solares CA, Tuohy VK. ELISPOT determination of interferon-γ T-cell frequencies in patients with autoimmune sensorineural hearing loss. Methods Mol. Biol. 302, 253-260 (2005).
46. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663-674 (2010).
47. Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res. 15(4), 1443-1451 (2009).
48. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a γ interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 8(5), 871-879 (2001).
49. Reece WH, Pinder M, Gothard PK et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10(4), 406-410 (2004).
50. Yang SH, Lee CG, Park SH et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-ofconcept study. Gene Ther. 13(14), 1110-1117 (2006).
51. Calarota SA, Foli A, Maserati R et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J. Immunol. 180(9), 5907-5915 (2008).
52. Goonetilleke N, Moore S, Dally L et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80(10), 4717-4728 (2006).
53. Ahlborg N, Axelsson B. Dual-and triple-color fluorospot. Methods Mol. Biol. 792, 77-85 (2012).
54. Gazagne A, Claret E, Wijdenes J et al. A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J. Immunol. Methods 283(1-2), 91-98 (2003).
55. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103(3), 966-972 (2004).
56. Janetzki S, Panageas KS, Ben-Porat L et al.; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57(3), 303-315 (2008).
57. Moodie Z, Price L, Gouttefangeas C et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59(10), 1489-1501 (2010).
58. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274(5284), 94-96 (1996).
59. Wagar LE, Rosella L, Crowcroft N et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One 6(11), e28063 (2011).
60. Aslam A, Chapel H, Ogg G. Direct ex-vivo evaluation of pneumococcal specific T-cells in healthy adults. PLoS One 6(10), e25367 (2011).
61. Schmidt J, Neumann-Haefelin C, Altay T et al. Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency. J. Virol. 85(10), 5232-5236 (2011).
62. Li Pira G, Ivaldi F, Moretti P, Manca F. High throughput T epitope mapping and vaccine development. J. Biomed. Biotechnol. 2010, 325720 (2010).
63. Wu C, Zanker D, Valkenburg S et al. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc. Natl Acad. Sci. USA 108(22), 9178-9183 (2011).
64. Ru Z, Xiao W, Pajot A et al. Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein. PLoS One 7(3), e32247 (2012).
65. Taneja V, David CS. HLA transgenic mice as humanized mouse models of disease and immunity. J. Clin. Invest. 101(5), 921-926 (1998).
66. Migueles SA, Osborne CM, Royce C et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29(6), 1009-1021 (2008).
67. Wonderlich J, Shearer G, Livingstone A, Brooks A. Induction and measurement of cytotoxic T lymphocyte activity. Curr. Protoc. Immunol. Chapter 3, Unit 3.11 (2006).
68. Krähenbühl O, Rey C, Jenne D et al. Characterization of granzymes A and B isolated from granules of cloned human cytotoxic T lymphocytes. J. Immunol. 141(10), 3471-3477 (1988).
69. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370(6491), 650-652 (1994).
70. Masson D, Tschopp J. Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J. Biol. Chem. 260(16), 9069-9072 (1985).
71. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14(2), 181-196 (1968).
72. Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev. Vaccines 9(6), 601-616 (2010).
73. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64(3), 313-320 (1983).
74. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115(1), 61-69 (1988).
75. Cui J, Bystryn JC. An improved europium release assay for complement-mediated cytolysis. J. Immunol. Methods 147(1), 13-19 (1992).
76. Bachy M, Bonnin-Rivalland A, Tilliet V, Trannoy E. β galactosidase release as an alternative to chromium release in cytotoxic T-cell assays. J. Immunol. Methods 230(1-2), 37-46 (1999).
77. Memon SA, Petrak D, Moreno MB, Zacharchuk CM. A simple assay for examining the effect of transiently expressed genes on programmed cell death. J. Immunol. Methods 180(1), 15-24 (1995).
78. Gupta P, Tayal R, Durgapal H, Rath S, Acharya SK, Panda SK. Development of highly sensitive Bicistronic vector based non-radioactive antigen-specific cytotoxicity assay. J. Immunol. Methods 349(1-2), 28-37 (2009).
79. Shafer-Weaver K, Sayers T, Strobl S et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med. 1(1), 14 (2003).
80. Zuber B, Levitsky V, Jönsson G et al. Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J. Immunol. Methods 302(1-2), 13-25 (2005).
81. Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol. Immunother. 61(2), 239-247 (2012).
82. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377(6548), 446-448 (1995).
83. Sarin A, Haddad EK, Henkart PA. Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J. Immunol. 161(6), 2810-2816 (1998).
84. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J. Immunol. Methods 304(1-2), 43-59 (2005).
85. Martin SJ, Reutelingsperger CP, McGahon AJ et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182(5), 1545-1556 (1995).
86. van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24(2), 131-139 (1996).
87. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184(1), 39-51 (1995).
88. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294(1-2), 15-22 (2004).
89. Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9(11), 1377-1382 (2003).
90. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281(1-2), 65-78 (2003).
91. Burkett MW, Shafer-Weaver KA, Strobl S, Baseler M, Malyguine A. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J. Immunother. 28(4), 396-402 (2005).
92. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat. Rev. Immunol. 8(2), 107-119 (2008).
93. Schmidt NW, Butler NS, Harty JT. Plasmodium-host interactions directly influence the threshold of memory CD8 T cells required for protective immunity. J. Immunol. 186(10), 5873-5884 (2011).
94. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 36(1), 142-152 (2012).
95. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754), 708-712 (1999).
96. Berard M, Tough DF. Qualitative differences between naïve and memory T cells. Immunology 106(2), 127-138 (2002).
97. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat. Immunol. 12(6), 467-471 (2011).
98. Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur. J. Immunol. 39(8), 2076-2082 (2009).
99. Hansen SG, Ford JC, Lewis MS et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348), 523-527 (2011).
100. Wherry EJ, Teichgräber V, Becker TC et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4(3), 225-234 (2003).
101. Buchbinder SP, Mehrotra DV, Duerr A et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
102. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275-1286 (2012).
103. Abate G, Eslick J, Newman FK et al. Flow-cytometric detection of vacciniainduced memory effector CD4(+), CD8(+), and γ Δ TCR(+) T cells capable of antigenspecific expansion and effector functions. J. Infect. Dis. 192(8), 1362-1371 (2005).
104. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat. Med. 11(10), 1113-1117 (2005).
105. Bendall SC, Simonds EF, Qiu P et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332(6030), 687-696 (2011).
106. Downey JS, Attaf M, Moyle G, Gazzard B, Gotch F, Imami N. T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness. AIDS 25(16), 1981-1986 (2011).
107. Puronen CE, Thompson WL, Imamichi H et al. Decreased interleukin 7 responsiveness of T lymphocytes in patients with idiopathic CD4 lymphopenia. J. Infect. Dis. 205(9), 1382-1390 (2012).
108. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin. Infect. Dis. 19(1), 26-32 (1994).
109. Nagafuchi S, Kashiwagi S, Hayashi J, Katsuta H, Ikematsu H, Harada M. A delayed type hypersensitivity (DTH) skin reaction to hepatitis B surface antigen (HBsAg) and intradermal hepatitis B vaccination. Fukuoka Igaku Zasshi 95(12), 305-313 (2004).
110. Koff WC. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30(29), 4310-4315 (2012).
111. Middleton JR. Staphylococcus aureus antigens and challenges in vaccine development. Expert Rev. Vaccines 7(6), 805-815 (2008).
112. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. Dis. 54(8), 1179-1186 (2012).
113. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 12(3), 191-200 (2012).
114. Janetzki S, Britten CM, Kalos M et al. 'MIATA'-minimal information about T cell assays. Immunity 31(4), 527-528 (2009).